Treatment of arterial hypertension in obese patients

Contributions to Nephrology

Volumn 151, Issue , 2006, Pages 230-242

  Wenzel, Ulrich O ^a   Krebs, Christian ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

HUMAN; OBESITY; PRACTICE GUIDELINE; RENOVASCULAR HYPERTENSION; REVIEW;

ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION, RENAL; OBESITY; PRACTICE GUIDELINES;

EID: 33748057832     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000095333     Document Type: Review

References (41)

1. Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V: Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries. Int J Obes Relat Metab Disord 2002;26:48-57.
2. Bramlage P, Pittrow D, Wittchen HU, Kirch W, Boehler S, Lehnert H, Hoefler M, Unger T, Sharma AM: Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004;17:904-910.
3. Frohlich ED: Clinical management of the obese hypertensive patient. Cardiol Rev 2002;10:127-138.
4. Zanella MT, Kohlmann O Jr, Ribeiro AB: Treatment of obesity hypertension and diabetes syndrome. Hypertension 2001;38(pt 2):705-708.
5. Sharma AM: Is there a rationale for angiotensin blockade in the management of obesity hypertension? Hypertension 2004;44:12-19.
6. Sharma AM, Pischon T, Engeli S, Scholze J: Choice of drug treatment for obesity related hypertension: where is the evidence? J Hypertens 2001;19:667-674.
7. Sharma AM, Rossner S: Who cares about the obese hypertensive patient? J Intern Med 2002;251:369-371.
8. Dentali F, Sharma AM, Douketis JD: Management of hypertension in overweight and obese patients: a practical guide for clinicians. Curr Hypertens Rep 2005;7:330-336.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
10. Engeli S, Sharma AM: Emerging concepts in the pathophysiology and treatment of obesity-associated hypertension. Curr Opin Cardiol 2002;17:355-359.
11. Jones DW, Miller ME, Wofford MR, Anderson DC Jr, Cameron ME, Willoughby DL, Adair CT, King NS: The effect of weight loss intervention on antihypertensive medication requirements in the hypertension Optimal Treatment (HOT) study. Am J Hypertens 1999;12(pt 1-2):1175-1180.
12. Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
13. Rocchini AP: Cardiovascular regulation in obesity-induced hypertension. Hypertension 1992;19(suppl):I56-160.
14. Wofford MR, Hall JE: Pathophysiology and treatment of obesity hypertension. Curr Pharm Des 2004;10:3621-3637.
15. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
16. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000;283:1967-1975.
17. Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35.
18. Lip GY, Beevers M, Beevers DG: The 'Birmingham Hypertension Square' for the optimum choice of add-in drugs in the management of resistant hypertension. J Hum Hypertens 1998;12:761-763.
19. Sharma AM, Pischon T, Hardt S, Kunz I, Luft FC: Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 2001;37:250-254.
20. Lindholm LH, Carlberg B, Samuelsson O: Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet, 2005;366:1545-1553.
21. Schmieder RE, Gatzka C, Schachinger H, Schobel H, Ruddel H: Obesity as a determinant for response to antihypertensive treatment. BMJ 1993;307:537-540.
22. White WB, Elliott WJ, Johnson MF, Black HR: Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension. J Hum Hypertens 2001;15: 135-141.
23. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-2013.
24. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
25. Basso N, Terragno NA: History about the discovery of the renin-angiotensin system. Hypertension 2001;38:1246-1249.
26. Wenzel UO: Angiotensin-converting enzyme inhibitors and progression of renal disease: evidence from clinical studies. Contrib Nephrol 2001;135:200-211.
27. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression of renal disease: from hemodynamics to cell biology. Nephron Physiol 2003;93:P3-P13.
28. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
29. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs 2004;64:2537-2565.
30. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
31. Grassi G, Seravalle G, Dell'Oro R, Trevano FQ, Bombelli M, Scopelliti F, Facchini A, Mancia G: Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity, and sympathetic drive in obese hypertensive individuals: results of the CROSS study. J Hypertens 2003;21:1761-1769.
32. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
33. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799-812.
34. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004;43:993-1002.
35. Schupp M, Janke J, Clasen R, Unger T, Kintscher U: Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004;109:2054-2057.
36. Schupp M, Lee LD, Frost N, Umbreen S, Schmidt B, Unger T, Kintscher U: Regulation of peroxisome proliferator-activated receptor gamma activity by losartan metabolites. Hypertension 2006;47:586-589.
37. Müller DN, Luft FC: Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006;1:221-228.
38. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W: Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-113.
39. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD: Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109: 1417-1427.
40. Pollare T, Lithell H, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-420.
41. Wenzel U, Wolf G: Blood pressure independent effects of antihypertensive agents. Internist 2005;46:548-556.